Acotec Scientific Holdings Limited (6669.HK)

Acotec Scientific Holdings Limited operates as an interventional medical device company that offers vascular interventional treatment products in Mainland China and internationally. The company's products include AcoArt Orchid & Dhalia, a paclitaxel DCB used to prevent stenosis or occlusion in superficial femoral artery and popliteal artery for the treatment of lower extremity artery disease with a vascular interventional approach; and AcoArt Tulip & Litos, a paclitaxel coated DCB used to prevent stenosis or occlusion in below-theknee arteries for the treatment of chronic limb-threatening ischemia with a vascular interventional approach. It also offers devices for vascular surgery, including AcoArt Iris & Jasmin; AcoArt Lily & Rosmarin; peripheral aspiration system; radiofrequency ablation system; peripheral support catheter; The PTA balloon; 2nd gen peripheral aspiration system; introducer sheath set; and the delivery catheter for aspiration catheter. In addition, it offers cardiology devices, including semi-compliant PTCA balloon; coronary CTO recanalization balloon; coronary CTO antegrade micro-catheter; coronary high-pressure balloon; cardiac valve balloon dilation catheter; AcoArt Camellia; and coronary micro-catheter. Further, the company provides nephrology devices, such as paclitaxel coated high-pressure balloon and AV scoring balloon; and neurology devices comprising intracranial PTA balloons and vertebral artery paclitaxel-coated balloon dilatation catheter, as well as trades in procedural medical devices. The company was founded in 2011 and is headquartered in Beijing, China. Acotec Scientific Holdings Limited operates as a subsidiary of Boston Scientific Group plc.